Stockscreener 앱 받기
71.33
0.46%
0.33
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
Nektar Therapeutics closes $460 million public offering By Investing.com - Investing.com India
Nektar Therapeutics Secures Major Funding as Shares Rally - AD HOC NEWS
Nektar Therapeutics closes $460 million public offering - Investing.com
Biotech Nektar raises $460M selling new shares and warrants - Stock Titan
Nektar Therapeutics (NKTR) Is Up 88.9% After Upsized Equity Raise And Positive REZOLVE-AD DataHas The Bull Case Changed? - Sahm
Can NKTR Stock Sustain Its 1,000% Rally? - Forbes
Nektar Stock: $400M Dilution And A Make-Or-Break Phase 3 - Trefis
Nektar Therapeutics Prices Upsized Public Equity Offering - TipRanks
Nektar Therapeutics stock hits 52-week high at 66.97 USD By Investing.com - Investing.com Nigeria
Nektar Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView
Why Nektar Therapeutics (NKTR) Is Up 102.2% After Strong REZOLVE-AD Data And $400 Million Raise - Yahoo Finance
Nektar Therapeutics prices $400M stock offering - MSN
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
Nektar CEO looks to add $400 milllion for atopic dermatitis drug - The Business Journals
Nektar Therapeutics stock falls after $400 million public offering By Investing.com - Investing.com UK
Nektar Therapeutics (NASDAQ:NKTR) Sets New 12-Month HighHere's Why - MarketBeat
Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up - simplywall.st
HC Wainwright Expects Lower Earnings for Nektar Therapeutics - MarketBeat
Nektar Therapeutics Prices $400 Million Offering of Stock, Pre-Funded Warrants - marketscreener.com
Nektar Therapeutics (NKTR) Finalizes $400M Stock Offering - GuruFocus
Nektar Therapeutics announces pricing of upsized $400 million public offering - marketscreener.com
Nektar Therapeutics Announces Pricing Of Upsized $400 Million Public Offering - TradingView
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering - PR Newswire
Nektar Therapeutics Announces Proposed Public Offering - The Malaysian Reserve
Rezpegaldesleukin maintenance data show durable responses in moderate-to-severe atopic dermatitis - Contemporary Pediatrics
Nektar Therapeutics stock pops on $300M equity offering - MSN
Nektar Stock Soars Amid Promising Developments and Analyst Upgrades - StocksToTrade
Nektar seeks US$300m for promising eczema drug - ifr-logo
Nektar Therapeutics stock hits 52-week high at 66.97 USD - Investing.com
Nektar Stock Surges On Rezpegaldesleukin Phase 2b Maintenance Data: What It Means - Seeking Alpha
Nektar’s Rezpegaldesleukin Shows Promise, Analysts Raise Price Targets - timothysykes.com
Nektar Therapeutics (NASDAQ:NKTR) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
BTIG Lifts Nektar Price Target Amidst Promising Atopic Dermatitis Treatment - StocksToTrade
Nektar Therapeutics (NKTR) Shares Surge on $300M Public Offering Announcement - GuruFocus
Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? - Nasdaq
Nektar’s Rezpeg Differentiates in Atopic Dermatitis With Durable, Deep Responses in Mid-Stage - BioSpace
A Quick Look at Today's Ratings for Nektar Therapeutics(NKTR.US), With a Forecast Between $102 to $165 - 富途牛牛
Nektar Shares Surge On Phase IIb Rezpeg Atopic Dermatitis Data - Citeline News & Insights
Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win - Yahoo Finance
Q3 EPS Forecast for Nektar Therapeutics Boosted by Analyst - MarketBeat
Why Is Nektar Therapeutics Stock Gaining Wednesday? - Benzinga
Biopharma companies Evommune and Nektar soar on eczema treatment data - Mugglehead Investment Magazine
Nektar Therapeutics (NKTR) stock jumps again premarket after 51% surge; $300 million offering in focus - Bez Kabli
Nektar reports positive long-term data for atopic dermatitis drug By Investing.com - Investing.com South Africa
Nektar lands upsized US$400m for eczema drug - ifr-logo
Nektar Therapeutics announces $300 million public offering By Investing.com - Investing.com South Africa
Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 - MarketBeat
BTIG Maintains Buy on Nektar Therapeutics (NKTR) Feb 2026 - Meyka
Nektar Therapeutics (NKTR) Launches $300M Stock Offering - GuruFocus
Nektar Therapeutics stock price target raised to $151 by BTIG - Investing.com UK
Evommune, Nektar assets join list of recent successes in atopic derm - biocentury.com
Evommune, Nektar soar on atopic dermatitis phase II data - BioWorld MedTech
Nektar Therapeutics announces $300 million public offering - Investing.com
Maintenance results boost Nektar's case for IL-2 agonist in atopic dermatitis - FirstWord Pharma
Nektar Therapeutics launches $300 mln equity offering after stock soars - TradingView
Double Trouble For Dupixent? Biotechs Fly On Eczema Tests. - Investor's Business Daily
Nektar Therapeutics (NKTR) Receives Boost with Analyst PT Raise | NKTR Stock News - GuruFocus
Nektar Therapeutics (NKTR) Analyst Rating Update: Price Target R - GuruFocus
1.12%
0.87%
자본화:
|
볼륨(24시간):